<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04447274</url>
  </required_header>
  <id_info>
    <org_study_id>UPS and ASPS-IIT-SHR1210</org_study_id>
    <nct_id>NCT04447274</nct_id>
  </id_info>
  <brief_title>A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS</brief_title>
  <official_title>A Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target&#xD;
      population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and&#xD;
      Alveolar Soft Tissue Sarcoma (ASPS) .&#xD;
&#xD;
      The purpose of this study was to evaluate the safety and efficacy of combination of&#xD;
      Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, eligible subject to accept study treatment. Camrelizumab combined with&#xD;
      apatinib is a treatment cycle every 2 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free rate at 12 weeks (PFR 12weeks)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The RECIST 1.1 standard was used to evaluate the disease progression and the 12 week progression free rate was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>6.5 months</time_frame>
    <description>It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>6.5 months</time_frame>
    <description>Refers to the date from the beginning of treatment to the first occurrence of disease progression or death caused by any reason, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response（DOR)</measure>
    <time_frame>6.5 months</time_frame>
    <description>Time from the first assessment of Cr or PR to the first assessment of PD or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab and Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab and Apatinib</intervention_name>
    <description>Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles</description>
    <arm_group_label>Camrelizumab and Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects &gt;/= 16 years of age at the time of Informed Consent,male or female;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;&#xD;
&#xD;
          3. Life expectancy of at least three months;&#xD;
&#xD;
          4. Advanced undifferentiated pleomorphic sarcoma (UPS) confirmed by histopathology,&#xD;
             patients who have failed in the first-line treatment and have progressed for 6 months;&#xD;
             advanced acinar soft tissue sarcoma (ASPS) confirmed by histopathology, patients who&#xD;
             have not been treated or who have failed in the first-line anti vascular drug&#xD;
             treatment and progressed within 6 months;&#xD;
&#xD;
          5. Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard&#xD;
             (the CT scan length of the tumor lesion &gt; 10 mm;&#xD;
&#xD;
          6. All acute toxic reactions caused by previous anti-tumor treatment were relieved to 0-1&#xD;
             level before enrollment (according to NCI CTCAE 5.03) Version) or to the level&#xD;
             specified in the inclusion / exclusion criteria (except for the toxicity that&#xD;
             researchers think does not pose a safety risk to subjects, such as hair loss); if&#xD;
             subjects undergo major surgery, they must have fully recovered from complications&#xD;
             before starting treatment;&#xD;
&#xD;
          7. The main organ function is normal. All baseline laboratory requirements will be&#xD;
             assessed and should be obtained within -14 days of randomization. Screening laboratory&#xD;
             values must meet the following criteria.&#xD;
&#xD;
               1. Hemoglobin ≥ 8.0 g/dL (90 g/L)&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 1.5× 109/L&#xD;
&#xD;
               3. Platelets ≥ 80× 109/L&#xD;
&#xD;
               4. Total bilirubin (TBIL) &lt; 1.5 × upper limit of normal (ULN)&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 × upper&#xD;
                  limit of normal(ULN);but &lt; 5uln in patients with liver metastasis, alkaline&#xD;
                  phosphatase &lt; 5 × ULN&#xD;
&#xD;
               6. Serum creatinine ≤ 1× ULN or creatinine clearance &gt; 45 mL/minute (using&#xD;
                  Cockcroft/Gault formula);&#xD;
&#xD;
          8. Women of childbearing age must have taken reliable contraceptive measures or carried&#xD;
             out pregnancy test (serum or urine) within 7 days before entering the group, and the&#xD;
             result is negative, and they are willing to use appropriate contraceptive methods&#xD;
             during the test and 60 days after the last administration of test drugs. For men, they&#xD;
             must agree to use appropriate methods of contraception or have undergone surgical&#xD;
             sterilization during the trial period and within 120 days after the last&#xD;
             administration of the trial drug;&#xD;
&#xD;
          9. Subjects should be voluntarily participate in clinical studies and informed consent&#xD;
             should be signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active central nervous system (CNS) metastasis and / or cancerous meningitis.&#xD;
             Subjects who had previously received brain metastases may participate as long as they&#xD;
             are stable and meet the following criteria: there is no evidence of imaging progress&#xD;
             for at least four weeks prior to the first dose of trial treatment, and any&#xD;
             neurological symptoms have returned to baseline, there is no evidence of new or&#xD;
             expanded brain metastases, and steroids are not used for at least seven days prior to&#xD;
             the trial treatment. This exception does not include cancerous meningitis, regardless&#xD;
             of its clinical stability;&#xD;
&#xD;
          2. Immunosuppressive drugs were used within 14 days before the first use of carrizumab,&#xD;
             excluding nasal spray and inhaled corticosteroids or systemic steroids with&#xD;
             physiological dose (i.e. no more than 10 mg / day of prednisolone or other&#xD;
             corticosteroids with physiological dose of the same drug); 3. Previously received the&#xD;
             following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs for another&#xD;
             stimulation or synergistic inhibition of T cell receptor (for example, CTLA-4, OX-40,&#xD;
             CD137); 4. Uncontrollable hypertension (systolic blood pressure ≥ 140 mmHg or&#xD;
             diastolic blood pressure ≥ 90 mmHg, despite systematic medication); 5. Severe&#xD;
             cardiovascular disease: myocardial ischemia or myocardial infarction above grade II,&#xD;
             poor control of arrhythmia (including QTc interval ≥ 450 ms for men and 470 MS for&#xD;
             women); cardiac insufficiency of grade III-IV (according to NYHA classification of New&#xD;
             York Heart Association, see Annex 3), or left ventricular ejection fraction (LVEF) &lt;&#xD;
             50% indicated by color Doppler echocardiography; 6. Patients with any active&#xD;
             autoimmune disease or history of autoimmune disease (including but not limited to:&#xD;
             autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis,&#xD;
             vasculitis, nephritis, hyperthyroidism, hypothyroidism) shall not be included; 7. The&#xD;
             subjects received systematic treatment such as bronchodilator, and the asthma control&#xD;
             was not satisfactory and could not be included (the asthma in childhood has been&#xD;
             completely relieved, and the adult can be included without any intervention); 8.&#xD;
             Routine urine test indicated that urine protein was ≥ 1.0g, or 24-hour urine protein&#xD;
             was ≥ 1.0g; 9. Abnormal coagulation (INR &gt; 1.5 ULN or prothrombin time (PT) &gt; ULN + 4&#xD;
             seconds or APTT &gt; 1.5 ULN), with bleeding tendency or undergoing thrombolysis or&#xD;
             anticoagulation treatment; Note: on the premise that the international standard ratio&#xD;
             of prothrombin time (INR) is less than or equal to 1.5, it is allowed to use low-dose&#xD;
             heparin (6000-12000 u daily for adults) or aspirin (less than or equal to 100 mg&#xD;
             daily) for prevention purposes; 10. Severe infection (such as intravenous drip of&#xD;
             antibiotics, antifungal drugs or antiviral drugs) occurred within 4 weeks before the&#xD;
             first administration, or fever of unknown cause occurred during screening / before the&#xD;
             first administration &gt; 38.5 ° C; 11. Serious arteriovenous thrombotic events occurred&#xD;
             in the first 12 months, such as cerebrovascular accident (including temporary ischemic&#xD;
             attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary&#xD;
             embolism; 12. In the first 4 weeks of the group, they had undergone major surgery or&#xD;
             had severe traumatic injury, fracture or ulcer; 13. Human immunodeficiency virus (HIV)&#xD;
             infection or known acquired immunodeficiency syndrome (AIDS), active tuberculosis,&#xD;
             active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive, and&#xD;
             HCV-RNA higher than the detection limit of the analysis method) or co infection with&#xD;
             hepatitis B and C; 14. Patients with a clear history of allergy may be potentially&#xD;
             allergic or intolerant to the biological agents of apatinib and carrizumab; 15. There&#xD;
             are obvious factors affecting the absorption of oral drugs, such as inability to&#xD;
             swallow, chronic diarrhea and intestinal obstruction. Or there were cavity organ sinus&#xD;
             or perforation within 6 months; 16. Those who have a history of abuse of psychotropic&#xD;
             substances and are unable to give up or have mental disorders; 17. Increase the risk&#xD;
             associated with participating in the study or study drug, and other circumstances&#xD;
             that, in the judgment of the investigator, may result in the patient not being&#xD;
             eligible for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihebali Chi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <phone>13911075626</phone>
    <email>yihebalichi6@126.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>yihebali chi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <keyword>UPS</keyword>
  <keyword>ASPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

